Research programme: cancer therapy adjuvants - VG Life Sciences

Drug Profile

Research programme: cancer therapy adjuvants - VG Life Sciences

Alternative Names: 2-deoxyglucose/etomoxir - MetaCytoLytics; Dichloroacetic acid - MetaCytoLytics; MDT compounds - MetaCytoLytics

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Colorado Foundation; University of Vermont
  • Developer VG Life Sciences
  • Class Acetates; Deoxy sugars; Epoxy compounds
  • Mechanism of Action Antimetabolites; Carnitine O-palmitoyltransferase inhibitors; Enzyme inhibitors; Glucose modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours(Late-stage disease, Adjuvant therapy) in USA
  • 30 Nov 2012 Viral Genetics is now called VG Life Sciences
  • 23 May 2012 Viral Genetics plans a clinical trial for Ovarian cancer (adjuvant therapy, late-stage disease) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top